

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO-CQ) FOR THE SYSTEMATIC ASSESSMENT OF ACROMEGALY COMORBIDITIES AT DIAGNOSIS AND THEIR MANAGEMENT AT FOLLOW-UP**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1564972> since 2017-09-19T09:57:01Z

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Guaraldi, F.; Gori, D.; Beccuti, G.; Prencipe, N.; Giordano, R.; Mints, Y.; Di Giacomo, V. S.; Berton, A.; Gasco, V.; Ghigo, E.; Salvatori, R.; Grottoli, S..  
USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO-CQ) FOR  
THE SYSTEMATIC ASSESSMENT OF ACROMEGALY  
COMORBIDITIES AT DIAGNOSIS AND THEIR MANAGEMENT AT  
FOLLOW-UP. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION.  
None pp: 1-6.

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/1564972>

**USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO- CQ) FOR THE  
SYSTEMATIC ASSESSMENT OF ACROMEGALY COMORBIDITIES AT DIAGNOSIS  
AND THEIR MANAGEMENT AT FOLLOW- UP**

F. Guaraldi<sup>1</sup> • D. Gori<sup>2</sup> • G. Beccuti<sup>1</sup> • N. Prencipe<sup>1</sup> • R. Giordano<sup>1,3</sup> • Y. Mints<sup>4</sup> •

V. S. Di Giacomo<sup>1</sup> • A. Berton<sup>1</sup> • M. Lorente<sup>1</sup> • V. Gasco<sup>1</sup> • E. Ghigo<sup>1</sup> • R. Salvatori<sup>4</sup> •

S. Grottoli<sup>1</sup>

\* F. Guaraldi

federica.guaraldi@unito.it; federica.guaraldi@yahoo.it

1 Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences,  
University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy

2 Department of Biomedical and Neuromotor Sciences, DIBINEM, University of Bologna,  
40126 Bologna, Italy

3 Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy

4 Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Pituitary  
Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

**Key words:** Acromegaly • Comorbidities • Complications • Pituitary adenoma • Questionnaire  
validity

## **Abstract**

**Purpose** To determine the validity of a self-administered questionnaire (Acro-CQ) developed to systematically assess the presence, type and time of onset of acromegaly comorbidities.

**Methods** This is a cross-sectional study; 105 acromegaly patients and 147 controls with other types of pituitary adenoma, referred to a specialized Italian Center, autonomously compiled Acro-CQ in an outpatient clinical setting. To test its reliability in a different setting, Acro-CQ was administered via mail to 78 patients with acromegaly and 100 with other pituitary adenomas, referred to a specialized US Center. Data obtained from questionnaires in both settings were compared with medical records (gold standard). **Results** Demographics of patients and controls from both countries were similar. In both settings, >95 % of the questionnaires were completely filled; only one item was missed in the others. Concordance with medical record was excellent ( $k > 0.85$ ) for most of the items, independently from the way of administration, patient age, gender and nationality, pituitary adenoma type and disease activity.

**Conclusions** Acro-CQ is an inexpensive, highly accepted from patients and reliable tool recommended to expedite systematic collection of relevant clinical data in acromegaly at diagnosis, to be replicated at follow-ups. This tool may guide a targeted, cost-effective management of complications. Moreover, it could be applied to retrieve data for survey studies in both acromegaly and other pituitary adenomas, as information is easily and rapidly accessible for statistical analysis.

## **Introduction**

Acromegaly is a rare disorder resulting from chronic hypersecretion of growth hormone (GH), mostly caused by a pituitary adenoma [1]. It mainly occurs sporadically, but may be seen in familial diseases [2]. It is characterized by dysmorphic facial and body features, anatomic and functional alterations of internal organs, metabolic, neoplastic and cardiovascular diseases (CVD), neurological symptoms and hypopituitarism secondary to adenoma mass effect, overall responsible for high morbidity and mortality [1, 3, 4]. Because of the disease complexity and the variable physician approach to patients, it is difficult to obtain a systematic assessment of the numerous complications induced by GH hypersecretion—whose risk and severity are related to disease duration and not always reversed by biochemical control—and its treatments [3, 5] and to replicate it at the various follow-ups. Moreover, because of economic restrictions imposed to the healthcare systems, a more personalized, cost-effective screening of complications would be very important in these patients.

Based on these premises, our study aimed at assessing the validity of a questionnaire purposely developed to systematically assess, at diagnosis and during follow-up, the type, prevalence and time of onset of relevant disorders typically associated with acromegaly and its treatments, to be used in the clinical practice for a patient-targeted cost-effective management.

## **Materials and methods**

Two hundred and fifty-two patients, 105 with acromegaly due to a GH-secreting adenoma (cases; 66 F; mean age  $59.0 \pm 14.8$  years) and 147 with other types of pituitary adenoma (controls; 87 prolactinomas and 60 non-functioning adenomas, NFA; 80 F; mean age  $55.0 \pm 16.1$  years) consecutively referred to the Division of Endocrinology, Diabetes and Metabolism, University of Turin (Italy) from November 2012 to May 2014, were evaluated.

The diagnosis of acromegaly was based on the presence of suggestive clinical features associated with MRI evidence of a pituitary adenoma, elevated age-adjusted IGF-I levels and nadir GH after oral glucose load  $>1 \mu\text{g/l}$  [5]. Disease was considered controlled in the presence of normal age- and gender-adjusted serum IGF-I levels and random GH  $< 1 \mu\text{g/l}$  during treatment and cured when these criteria were fulfilled after treatment discontinuation [5]. Prolactinoma was diagnosed in the presence of elevated serum prolactin levels and MRI evidence of pituitary adenoma, after excluding other causes of hyperprolactinemia and mixed GH-/PRL-secreting tumors. Prolactin levels at diagnosis, together with clinical, biochemical and radiological findings and (in some cases) response to therapy with dopamine agonists, contributed to differential diagnosis between prolactinomas and NFA [6]. Remission was defined as serum prolactin level in the normal range during medical treatment; patients were considered cured when prolactin levels were in the normal range after treatment discontinuation. NFA was defined as MRI-detected pituitary adenoma in the absence of hormone hypersecretion [7]. Patients with hypopituitarism were adequately substituted with hormonal replacement therapy.

Patients were asked to fill, in an outpatient setting, a self-administered, 22-item questionnaire (AcroCQ), purposely developed to systematically assess the presence of (1) comorbidities typically associated with acromegaly and its treatment, including metabolic (glucose, lipid and bone metabolism), CVD and neoplastic disorders; intestinal diverticulosis/diverticulitis; gallbladder and kidney stones; and goiter and carpal tunnel syndrome and (2) family history of pituitary adenoma. For each comorbidity, patients were also asked to indicate their age at diagnosis, and for neoplasia, the type and location (Fig. 1).

The choice of comorbidities to be investigated by the questionnaire was made by a team of neuroendocrinologists based on their clinical practice and expert reviews/ international guidelines: Disorders typically associated with acromegaly and deserving treatment to prevent long-term morbidity and mortality were included [3, 5, 8]. To improve patient understanding and compliance, we formulated simple and direct questions, using the easiest possible terms.

To determine Acro-CQ validity, the same data collected through questionnaire's administration were retrieved from medical records—considered the gold standard—together with information on adenoma size at diagnosis, hormonal parameters at diagnosis and follow-up (to determine disease activity and the adequacy of replacement therapy in case of hypopituitarism), the presence of residual adenoma and type and duration of the various treatments.

With regard to associated disorders (“comorbidities”), acromegaly patients had been screened at diagnosis and follow-up according to international guidelines [9], while controls had been evaluated only in the presence of suggestive symptoms and/or risk factors. Based on the established promoting role of chronic GH hypersecretion on the development of systemic disorders and the mean reported delay in acromegaly diagnosis (2.5–10 years on average) [8], comorbidities diagnosed  $\leq 5$  years before acromegaly were arbitrarily defined “complications”, and those affecting  $\geq 10$  patients were considered “common”.

Hypertension was defined as a systolic blood pressure  $\geq 140$  mmHg and/or a diastolic blood pressure  $\geq 90$  mmHg or the use of antihypertensive drugs. International criteria were applied for the diagnosis of impaired fasting glucose, impaired glucose tolerance and diabetes [10], dyslipidemia [11], osteopenia and osteoporosis [12]. The diagnosis of thyroid hyperplasia/goiter was established by ultrasound examination.

To confirm the concordance between self-reported disease and medical record in a different geographical setting, the study was extended to 178 patients, 78 with acromegaly and 100 with other pituitary adenomas, referred to the Pituitary Center of the Johns Hopkins University Hospital, Baltimore (USA). At this purpose, Acro-CQ, originally formulated in Italian, was translated in English and reviewed by a native speaker. Patients were contacted by mail, filled the questionnaire at home and returned it by mail using prepaid stamped envelopes.

The questionnaire was returned by 35 acromegaly patients (20 F; mean age  $56.1 \pm 11.6$  years) and 40 patients with other types of pituitary adenoma (controls; 21 F; mean age  $59.3 \pm 11.0$  years; 14

prolactinomas and 26 NFA). Patients' main demographics and clinical characteristics are summarized in Table 1.

The study was approved by the Hospital Ethics Committees of both Turin University and Johns Hopkins University. Only patients able to autonomously read and fill the questionnaire and give their written informed consent to participate in the study were included.

### **Statistical analysis**

Prevalence of comorbidities was defined for cases and controls; in patients with acromegaly, we also calculated the prevalence, temporal distribution and median time interval between diagnosis and complication's onset. Inter-group differences were assessed using Chi-square test or Fisher's exact test ( $n \leq 5$ ); a p value  $<0.05$  was considered statistically significant. Multivariate logistic regression analysis, adjusted for gender and age at time of response to the questionnaire, was performed to test differences in prevalence of comorbidities between groups; odds ratios were also calculated. The concordance between clinical record and questionnaire was evaluated by Cohen's Kappa coefficient [13]: For  $k \leq 0.6$ , logistic regression was performed to assess the influence of gender and age at evaluation (independent predictors of the model) on questionnaire response. Gender differences in answering to the questionnaire were calculated by Fisher's exact test.

Statistical analysis was performed with STATA Statistical Software, release 12 (StataCorp LP, College Station, TX, USA).

### **Results**



The groups of patients with acromegaly and controls from Italy and USA were homogeneous for gender and age distribution, at diagnosis of pituitary adenoma and at evaluation (Table 1).

Neoplasia was more frequently associated with acromegaly than other pituitary adenomas, although the statistical significance was reached only for gastrointestinal ( $p < 0.004$ ;  $p < 0.0001$  for colonic polyposis) and genitourinary neoplasia ( $p < 0.01$ ) (Supplementary Table 1). The great majority of the tumors, except for hematologic ones, were benign, as detailed in Table 2.

Acromegaly patients were at higher risk of metabolic abnormalities (impaired glucose tolerance; IGT/diabetes; dyslipidemia; osteopenia/osteoporosis), hypertension, hypertrophic/dilatative and valvular cardiac disorders ( $p < 0.0005$ ), but not for arrhythmias, ischemic events or aneurysms. Gallbladder ( $p < 0.0001$ ) and kidney stones ( $p < 0.004$ ), intestinal diverticulosis ( $p < 0.0001$ ), goiter ( $p < 0.0001$ ), obstructive sleep apnea ( $p = 0.004$ ) and carpal tunnel syndrome ( $p < 0.0001$ ) were also more frequent in acromegaly. The majority of complications appeared soon after acromegaly diagnosis (median  $\leq 5.5$  years) (Supplementary Table 1). In

both groups, patients typically developed gallbladder and kidney stones during SSA treatment (Supplementary Table 1).

Familial history of pituitary adenoma was present in four patients with acromegaly and one with NFA (4/5 were males).

In the Italian cohort, questionnaires were completely filled by 98.9 % of acromegaly patients, and by 95.7 % of the controls; only one item (typically diverticulosis, IGT/ diabetes and genitourinary benign neoplasia) was missing in incomplete questionnaires (Supplementary Table 2).

Concordance between questionnaire and medical record was good or excellent ( $k > 0.6$ ) for all items in both groups, except for genitourinary neoplasia ( $k = 0.54$ ), CVD ( $k = 0.45$ ) and dyslipidemia ( $k = 0.51$ ), underreported in acromegaly. Logistic regression analysis showed a higher number of mismatches in males for genitourinary benign neoplasia, but no gender differences for CVD and

dyslipidemia. Concordance between questionnaire and medical record was negatively associated with age at the time of questionnaire's compilation for genitourinary benign neoplasia, CVD and IGT.

The administration of Acro-CQ to the Baltimore cohort confirmed the excellent rate of e-questionnaire completion (97 % in acromegaly and 97.7 % in controls of the returned questionnaires were completely filled), as well the high concordance between questionnaire and medical record, being  $k > 0.7$  for all items except for thyroid hyperplasia ( $k = 0.4$ ), underreported in the control group.

## **Discussion**

We present the results of a cross-sectional study assessing the validity of Acro-CQ, the first questionnaire developed to systematically assess at diagnosis, and monitor during follow-up, the presence of comorbidities typically associated with acromegaly, thus improving patient management. Acromegaly is a chronic disease associated with a large number of comorbidities, typically presenting in the first years after diagnosis and not always reversed after disease control, responsible for a significant increase in morbidity, impairment of the quality of life and high mortality rate [1, 3–5]. At the same time, due to the disease complexity and variable physician approach to patients, it is currently difficult to obtain a systematic evaluation at diagnosis to be replicated at follow-ups. Moreover, because of economic restrictions imposed on the healthcare systems, a more personalized monitoring of complications would be extremely important for a cost-effective patient management. For this purpose, historical information retrieved from patients through validated tools could be extremely useful, especially for those with limited available medical data evaluated in specialized medical centers geographically far from their residence and referring physicians.

According to our data, Acro-CQ is a valid tool for an easy, comprehensive and inexpensive assessment and monitoring of acromegaly comorbidities. Indeed, the patient acceptance rate and concordance with medical record are very high, independently from patient age, gender, language and clinical setting. The success of the questionnaire is likely based on the clear format, close-ended questions with

dichotomous answers formulated using an easy and straightforward language [14, 15]. When questionnaire was mailed, the percentage of return was overall satisfactory (42 %). Providing patients with prepaid stamped envelopes may have increased the rate of response [16].

On the other hand, a minor limitation to the clinical application of the questionnaire at each follow-up visits could be the relatively long time needed to completely fill the questionnaire in patients with many comorbidities.

Moreover, being the questionnaire self-administered, we demonstrated for the first time that patients with acromegaly and, more generally, pituitary adenomas are highly aware about disorders associated with their condition.

Finally, using both questionnaires and medical records, the prevalence data of a great variety of disorders were retrieved from a large and homogeneous cohort of patients with acromegaly, for the first time compared to patients with other types of pituitary adenoma. Data analysis demonstrated a significantly higher prevalence of metabolic and cardiovascular disorders, as well as thyroid hyperplasia, carpal tunnel syndrome and intestinal diverticulosis in acromegaly than in other pituitary adenomas, confirming percentages obtained from previous studies considering acromegaly patients per se, or in comparison with healthy subjects [3, 17–22]. On the contrary, the prevalence of obstructive sleep apnea was lower in our cohort than previously reported (19 vs. 60–90 %) [3], underlining the importance of formal assessment of sleep disorders, as symptoms leading to polysomnography investigation are frequently underestimated.

Independently of the type of pituitary adenoma, a strong association was found between SSA therapy and the development of gallstones (confirming the literature data [23]) and kidney stones. Several mechanisms for which SSA contribute to gallstones formation have been postulated, leading to increased bile concentration and lithogenic changes in its composition, together with physical conditions favoring micro-crystal precipitation and stone formation. Conversely, mechanisms that could

cause SSA to predispose to kidney stones formation remain unknown, as chronic administration of SSA apparently does not impact on calcium metabolism [24].

Whether the risk of cancer and related mortality is increased by GH hypersecretion is debated [3, 20, 21, 25]. We found that the prevalence of neoplasia in acromegaly was not significantly higher than in other pituitary adenomas, except for gastrointestinal and genitourinary tumors (Supplementary Table 1), being the great majority of these lesions benign (Table 2). Rates of thyroid hyperplasia, gastrointestinal and genitourinary benign tumors were in line with the literature [3, 21, 26], but we did not observe the increased risk of malignant transformation of thyroid nodules and intestinal polyps reported by larger cohort studies and meta-analysis [3, 20, 21, 25], possibly due to the smaller sample size.

In conclusion, we recommend Acro-CQ for an easy, inexpensive, reproducible and comprehensive assessment of relevant comorbidities associated with acromegaly (but also with other pituitary adenomas), at diagnosis and follow-up visits, to guide a patient-targeted and cost-effective management. Because it takes a relatively long time to completely fill the questionnaire in patients with many comorbidities, physicians could decide in more complex patients, especially those requiring very frequent visits, to administer the Acro-CQ only during selected follow-up visits.

The Acro-CQ can also be used to retrieve data for survey studies in the field of pituitary disorders, as clinical information is easily and rapidly accessible for statistical analysis.

The application of this tool to larger cohorts of patients (i.e., multicenter studies) would be extremely useful to better determine the validity of the suggested tool, both in the clinical and research settings.

Compliance with ethical standards

Conflict of interest RS serves in an advisory board for Novartis and receives research support from Novartis, Ipsen and Pfizer. EG serves in an advisory board for Pfizer. SG serves in an advisory board

for Pfizer and received support from Novartis, Ipsen, Italfarmaco and Pfizer. The other authors declare they have no conflict of interest.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and the Helsinki Declaration. This article does not contain any studies with animals performed by any of the authors.

**Informed consent** All patients included in the study gave their informed consent.

**Funding** This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

## **References**

1. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. *Best Pract Res Clin Endocrinol Metab* 23:555–574
2. Daly AF, Beckers A (2015) Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. *Endocrinol Metab Clin North Am* 44:19–25
3. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. *Endocr Rev* 25:102–152
4. Jurcut R, Gațoiu S, Florian A, Vlađdaia A, Ioniță OR, Amzulescu MS, Baciuc I, Popescu BA, Cocolescu M, Ginghina C (2014) Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study. *J Endocrinol Invest* 37:1081–1090

5. Giustina A, Chanson P, Bronstein MD et al (2010) Acromegaly Consensus Group: a consensus on criteria for cure of acromegaly. *J Clin Endocrinol Metab* 95:3141–3148
6. Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 96:273–288
7. Molitch ME (2014) Nonfunctioning pituitary tumors. *Handb Clin Neurol* 124:167–184
8. Giustina A, Chanson P, Kleinberg D et al (2014) Acromegaly Consensus Group: expert consensus document: a consensus on the medical treatment of acromegaly. *Nat Rev Endocrinol* 10:243–248
9. Melmed S, Casanueva FF, Klibanski A et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. *Pituitary* 16:294–302
10. Rydén L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 34:3035–3087
11. Smith SC Jr, Grundy SM (2014) 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. *J Am Coll Cardiol* 64:601–612
12. Florence R, Allen S, Benedict L et al (2013) Diagnosis and treatment of osteoporosis. [http://www.icsi.org/\\_asset/vnw0c3/Osteo.pdf](http://www.icsi.org/_asset/vnw0c3/Osteo.pdf). Accessed 12 July 2015
13. Cohen J (1960) A coefficient of agreement for nominal scales. *Educ Psychol Meas* 20:37–46
14. Colosi L (2006) <http://www.human.cornell.edu/pam/outreach/parenting/parents/upload/Designing-20an-20Effective-20Questionnaire.pdf>. Accessed 12 July 2015
15. Burns KEA, Duffett M, Kho ME et al (2012) A guide for the design and conduct of self-administered surveys of clinicians. *Can Med Ass J* 179:245–252

16. Lavelle K, Todd C, Campbell M (2008) Do postage stamps versus pre-paid envelopes increase responses to patient mail surveys? A randomized controlled trial. *BMC Health Serv Res* 8:113
17. Alexopoulou O, Bex M, Kamenicky P, Bessomo Mvoula A, Chanson P, Maiter D (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. *Pituitary* 17:81–89
18. Mosca S, Paolillo S, Colao A et al (2013) Cardiovascular involvement in patients affected by acromegaly: an appraisal. *Int J Cardiol* 167:1712–1718
19. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A et al (2015) Bone turnover, bone mineral density and fracture risk in acromegaly: a meta-analysis. *J Clin Endocrinol Metab* 100:384–394
20. Reverter JL, Fajardo C, Resmini E et al (2014) Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? *PLoS One* 9:e104174
21. Jenkins PJ (2006) Cancers associated with acromegaly. *Neuroendocrinology* 83:218–223
22. Wassenaar MJ, Cazemier M, Biermasz NR et al (2010) Acromegaly is associated with an increased prevalence of colonic diverticula: a case–control study. *J Clin Endocrinol Metab* 95:2073–2079
23. Attanasio R, Mainolfi A, Grimaldi F et al (2008) Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. *J Endocrinol Invest* 31:704–710
24. Ajmal A, Haghshenas A, Attarian S et al (2014) The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. *Pituitary* 17:366–373. doi:10.1007/s11102-013-0514-0
25. Wolinski K, Czarnywojtek A, Ruchala M (2014) Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review. *PLoS One* 9:e88787
26. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G (2008) Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. *World J Gastroenterol* 14:3484–3489

Name ..... Surname ..... Date of birth .....

Pituitary adenoma type ..... Year of diagnosis .....

**1. Have you ever been diagnosed with a benign/malignant tumour of the central nervous system (excluding pituitary adenoma)?**  Yes  No

1a. If yes, which kind? Which location? .....

1b. What was your age at diagnosis .....

**2. Have you ever been diagnosed with a benign/malignant tumour in your face/head (eyes, mouth, nose, ears; skin, bones and muscles) or neck (thyroid, parathyroid glands; skin, muscles)?**  Yes  No

2a. If yes, which kind? Which location? .....

2b. What was your age at diagnosis .....

**3. Have you ever been diagnosed with a benign/malignant breast tumour?**  Yes  No

3a. If yes, which kind? Which location? .....

3b. What was your age at diagnosis .....

**4. Have you ever been diagnosed with a benign/malignant tumour of the respiratory apparatus (trachea/windpipe, airways, lungs)?**  Yes  No

4a. If yes, which kind? Which location? .....

4b. What was your age at diagnosis .....

**5. Have you ever been diagnosed with a benign/malignant tumour of the digestive system (esophagus, stomach, intestine, colon, rectum, liver, pancreas, gallbladder, bile ducts)?**  Yes  No

5a. If yes, which kind? Which location? .....

5b. What was your age at diagnosis .....

**6. Have you ever been diagnosed with a benign/malignant tumour of the urogenital tract (bladder; prostate, testicles for males; uterus, ovaries for females)?**  Yes  No

6a. If yes, which kind? Which location? .....

6b. What was your age at diagnosis .....

**7. Have you ever been diagnosed with a benign/malignant tumour of the adrenal gland?**  Yes  No

7a. If yes, which kind? Which location? .....

7b. What was your age at diagnosis .....

**8. Have you ever been diagnosed with a benign/malignant tumour of muscles or bones?**  Yes  No

8a. If yes, which kind? Which location? .....

8b. What was your age at diagnosis .....

**9. Have you ever been diagnosed with a benign/malignant tumour of the skin?**  Yes  No

9a. If yes, which kind? Which location? .....

9b. What was your age at diagnosis .....



- 10. Have you ever been diagnosed with a haematological malignancy (lymphoma, leukaemia, myeloma)?**  Yes  No
- 10a. If yes, which kind? Which location? .....
- 10b. What was your age at diagnosis .....
- 11. Do you suffer from gallbladder/bile ducts stones?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 12. Do you suffer from kidney stones?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 13. Do you suffer from reduced bone density (osteopenia/osteoporosis)?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 14. Do you suffer from intestinal diverticulosis/diverticulitis?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 15. Do you suffer from high blood pressure (hypertension)?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 16. Do you suffer from other cardiovascular diseases (ischaemic, valvular, rhythmic disorders; cardiomegaly/cardiac hypertrophy; vascular aneurysms; etc.)?**  Yes  No
- 16a. If yes, which kind? .....
- 16b. What was your age at diagnosis? .....
- 17. Do you suffer from impaired glucose intolerance/diabetes mellitus?**  Yes  No
- 17a. What was your age at diagnosis? .....
- 18. Do you suffer from increased cholesterol and/or triglycerides levels (hypercholesterolemia/hypertriglyceridemia)?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 19. Do you suffer from thyroid disorders excluded benign/malignant tumours (i.e. goitre, thyroiditis)?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 20. Have you ever been diagnosed with carpal tunnel syndrome?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 21. Do you suffer from sleep apnoea syndrome (OSAS)?**  Yes  No
- If yes, what was your age at diagnosis? .....
- 22. Has any of your family member been diagnosed with pituitary adenoma?**  Yes  No
- 22a. If yes, what's your degree of kinship with this person? .....
- 22b. What type of adenoma does this person suffer from? .....

**Table 1** Patients demographics and main clinical features

Group	N	F (%)	Age at diagnosis (yr; mean $\pm$ SD)	Age at evaluation (yr; mean $\pm$ SD)	Treatment					Residual tumor (%)	Hypopituitarism (%)
					Surgery (%)	RT (%)	Medical therapy				
							SSA (%)	D2 agonists (%)	Pegvisomant (%)		
<i>Acromegaly (cases)</i>											
Turin	105	62.8	47.0 $\pm$ 13.7	59.0 $\pm$ 14.8	56.2	21.9	94.3	53.3	27.6	70.5	36.2
Baltimore	35	51.2	47.0 $\pm$ 12.0	56.1 $\pm$ 11.6	91.4	28.6	62.8	31.4	31.4	48.6	34.3
<i>Other pituitary adenomas (controls)</i>											
Turin	147	54.4	45.0 $\pm$ 16.8	55.0 $\pm$ 16.1	34	4.7	5.4	63.9	0	70	38.1
Baltimore	40	52.5	49.9 $\pm$ 11.7	59.3 $\pm$ 11.0	60	0	0	32.5	0	70	42.5

*D2 agonists* dopamine agonists, *F* females, *N* number, *pts* patients, *RT* radiation therapy, *SD* standard deviation, *SSA* somatostatin analogues, *yr* years

**Table 2** Type and distribution of neoplasia in patients with acromegaly (cases) and other types of pituitary adenoma (controls) in the Turin cohort

Type of neoplasia	Acromegaly (N = 105)	Controls (N = 147)
<i>I. Central nervous system</i>		
Meningioma	6	2
Neurinoma	–	1
Craniopharyngioma	–	1
Neurofibroma	–	1
<i>II. Head and neck</i>		
Ethmoidal polyps	1	–
Epithelioma	1	1
Cavernous hemangioma	1	–
Papilloma	–	1
Oncocytoma	–	1
Thyroid papillary carcinoma	1	–
Parathyroid adenomas	3	–
<i>III. Breast cancer</i>		
Fibroadenoma	9	3
Lypoma	1	1
Carcinoma	1	3
<i>IV. Respiratory apparatus</i>		
Carcinoid	1	–
Differentiated neuroendocrine tumor	1	–
Neuroblastoma	–	1
<i>V. Gastrointestinal apparatus (excluding gastrointestinal polyps)</i>		
Hepatic hemangioma	9	1
Hepatic adenocarcinoma	1	–
Gallbladder adenomyoma	5	1
Intestinal lipoma	1	–
Colon carcinoma	1	1
Gastric adenoma	–	1
Gastric carcinoma	–	1
Mesenteric carcinoma	–	1
<i>VI. Genitourinary apparatus</i>		
Uterine leiomyoma	16	13
Uterine carcinoma	–	3
Ovarian cystadenoma	1	–
Prostate adenoma	16	14
Prostate carcinoma	–	1
Testicular teratoma	–	1
Renal adenoma	–	1
Renal angiomyolipoma	4	–
Renal oncocytoma	1	–
Renal carcinoma	3	2
Bladder carcinoma	1	3

**Table 2** continued

Type of neoplasia	Acromegaly (N = 105)	Controls (N = 147)
<i>VII. Adrenal gland</i>		
Incidentaloma	2	3
Hemangioma	–	1
<i>VIII. Muscle-skeleton apparatus</i>		
Lypoma	1	1
Neuroma	–	1
<i>IX. Skin</i>		
Hemangioma	1	–
Melanoma	2	–
Atypical melanocytic hyperplasia	–	1
Epithelioma	–	1
<i>X. Hematologic malignancies</i>		
Multiple myeloma	–	1
Non-Hodgkin lymphoma	–	1
Acute lymphoblastic leukemia	–	–